Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13
Authors:
Open Access
- 21 December 2006
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 136 (3) , 451-461
Abstract
Summary: Thrombotic thrombocytopenic purpura (TTP) is a life‐threatening disorder and plasma exchange (PEX) remains the primary treatment modality. Twenty‐five patients with acute refractory/relapsing idiopathic TTP received rituximab in conjunction with PEX because of progressive clinical disease or deterioration in laboratory parameters, despite intensive standard therapy. In relapsing TTP, rituximab was started if antibody to ADAMTS‐13 (a disintegrin and metalloproteinase with thrombospondin motif‐13) was demonstrated during previous episodes. All 25 patients attained complete clinical and laboratory remission in a median of 11 d after initiating rituximab. In 21 cases, ADAMTS‐13 activity was within the normal range following rituximab. Inhibitors were detected in 24/25 patients by mixing studies and/or immunoglobulin G (IgG) antibodies to ADAMTS‐13 pre‐rituximab. There was no evidence of inhibitors and/or IgG activity <10% in 23/25 patients following rituximab. In acute refractory cases, the median number of PEX pre‐rituximab and following the first rituximab infusion was 13 and 9, respectively. There have been no infectious complications, despite low CD 19 levels and no relapses. In patients with acute refractory/relapsing idiopathic TTP, rituximab appears to be a safe, effective, targeted therapy with a significant reduction in the requirement for PEX.Keywords
This publication has 34 references indexed in Scilit:
- Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic uremic syndromeTransfusion, 2005
- Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 casesBlood, 2005
- ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseasesBlood, 2005
- Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S‐59) and ultraviolet A lightTransfusion, 2005
- Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)American Journal of Hematology, 2004
- Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophiliaBlood, 2004
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three casesAmerican Journal of Hematology, 2004
- Nonneutralizing IgM and IgG antibodies to von Willebrand factor–cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpuraBlood, 2003
- Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximabAmerican Journal of Hematology, 2002